LOS ANGELES, CA — (Marketwired) — 11/04/13 — MyMedicalRecords, Inc., a wholly owned subsidiary of (OTCQB: MMRF) (collectively, “MMR”), today announced that the United States District Court, Central District of California, granted the Company-s motion to consolidate its complaint for patent infringement against Allscripts Healthcare Solutions, Inc. with its previously filed complaint against Jardogs, LLC. The order was granted on November 1, 2013, Case No. 2:13-cv-03560-ODW (SHx), and is available on the court-s website . Two days earlier the court also approved MMR-s request to amend its complaint against Quest Diagnostics Inc., Case No. CV-13-02538-CBM (MNx) to add a second patent, U.S. Patent No. 8,498,883, entitled “Method for Providing a User with a Service for Accessing and Collecting Prescriptions.” The Allscripts/Jardogs and Quest Diagnostics complaints each now involve two MyMedicalRecords U.S. patents: U.S. Patent No. 8,301,466, entitled “Method and System for Providing Online Records,” and U.S. Patent No. 8,498,883, entitled “Method for Providing a User with a Service for Accessing and Collecting Prescriptions.”
MMR first filed a complaint for patent infringement against Jardogs, LLC on May 31, 2013. The Company alleged that Jardogs- product, FollowMyHealth Universal Health Record, infringes on the “466” patent. On September 23, 2013, the Company filed suit against Allscripts Healthcare Solutions, Inc., alleging that Allscripts acquired Jardogs, rendering Allscripts liable for any patent infringement by Jardogs, and that Allscripts was infringing on the “466” patent, as well as the Company-s “883” patent.
In addition to the Company-s primary business of providing secure online under its patented brand, as well as its document management and imaging systems for healthcare professionals, MMR is also actively involved in licensing and protecting its global health information technology portfolio. This includes eight U.S. patents with hundreds of claims focused on the digital transmission of medical records, including Personal Health Records. Internationally, MMR has received issued patents and has pending applications in countries or regional authorities of commercial interest such as Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and Europe. Using its patented, proprietary technologies, the PHR facilitates, among other things, documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, e-mail, phone or file upload, creating an integrated telecommunications platform that does not rely on any specific EMR system to populate a user-s account. Additionally, in the event of an emergency or disaster, medical personnel and first responders can retrieve potentially lifesaving information via a separate emergency login to the patient-s PHR.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user-s account. The Company-s professional offering, , is designed to give physicians- offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin-s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company-s products and services at .
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management-s expectations, beliefs, intentions, estimates or projections, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR-s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “potential,” “intend,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR-s health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR-s products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market-s acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR-s filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Michael Selsman
Public Communications Co.
(310) 922-7033
You must be logged in to post a comment Login